GlassScriptPhysician profile
Christopher Steven Meier
NPI 1699033258
$2,572.15
in general payments reported to CMS, 2019-2025
31 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $101 · 2021: $274 · 2022: $353 · 2023: $696 · 2024: $582 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $554.37 | 2020-2025 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $255.81 | 2021-2025 | Erleada |
| Boston Scientific Corporation | $212.94 | 2019-2025 | Spaceoar Vue System - 10ml, Obtryx System - Curved, Spaceoar System |
| Pfizer INC. | $198.52 | 2021-2023 | |
| Biocompatibles, INC. | $192.93 | 2019 | |
| Sumitomo Pharma America, INC. | $110.74 | 2023-2025 | Gemtesa |
| Axonics, INC. | $110.38 | 2022-2024 | Bulkamid, Axonics |
| Teleflex LLC | $109.05 | 2021-2025 | Urolift, Barrigel |
| Abbvie INC. | $106.40 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $105.26 | 2024-2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $81.94 | 2022-2025 | Pylarify |
| Coloplast Corp | $70.07 | 2021-2022 | |
| Urogen Pharma, INC. | $59.98 | 2023-2024 | Jelmyto |
| Endo USA, INC. | $52.09 | 2024 | Aveed, Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $37.96 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.51 | 2024 | Keytruda |
| Intuitive Surgical, INC. | $26.87 | 2022 | |
| Dendreon Pharmaceuticals LLC | $24.46 | 2023 | Provenge |
| Medtronic, INC. | $24.04 | 2023 | Interstim |
| Calyxo, INC. | $22.60 | 2025 | Cvac Aspiration System |
| Accord Healthcare, INC. | $22.18 | 2024 | |
| Karl Storz Endoscopy-America | $21.24 | 2021 | |
| Myovant Sciences INC. | $20.53 | 2022 | |
| Photocure INC | $19.50 | 2020 | |
| Baxter Healthcare | $18.24 | 2021 | |
| Endo Pharmaceuticals INC. | $17.76 | 2020 | |
| Laborie Medical Technologies Corp. | $16.97 | 2023 | |
| Tolmar, INC. | $16.33 | 2024 | |
| Srs Medical Systems, INC. | $14.39 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.27 | 2023 | Oxlumo |
| Travere Therapeutics, INC. | $3.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.